Create your own awesome maps

Even on the go

with our free apps for iPhone, iPad and Android

Get Started

Already have an account?
Log In

ADPD Conference 2011, Barcelona, Spain by Mind Map: ADPD Conference 2011, Barcelona,
Spain
0.0 stars - reviews range from 0 to 5

ADPD Conference 2011, Barcelona, Spain

Day 1

Symposium 7

Symposium 7 Talk 1

Symposium 7 Talk 2 - Professor Fahnestock

Symposium 7 talk 3

Elan Sponsored Symposium: Hall A

E. Koo talk, Literature, Imbimbo, Petersen, NSAIDS and GMSs, GSM activity may be one explanation for the apparent protetcive function of NSAIDS in AD, No definitive in vivo evidence of target engagemetn by GMSs, Flurizan (R-flurbiprofen) did not adequately test amyloid hypothesis due to lack of activity/brain penetrations

J. McLaurin, Fenili et al, J Mol Med 2007, McLaurin et al, Nat Med 12, 801-8-2006, More papers by author, Open access papers, Chishti 2001

J.O. Rinne, Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's Disease, Rinne 2010, Lancet Paper, Paper on Amyloid PET imaging, Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. (open access paper), Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease, Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain

M. Buttini, What's an ideal animal model for Parkinson's Disease, Toxin models, primates, rodents, e.g. MTPT, "viral models", expressionof familial PD genes in the SN of rats using a viral construct, Mouse models, transgenic expression of familial PD genes using a variety of promotersor expression cassettes, Transgenic mice for Afa synuclein, Tyrosine hydroxylase promoter, Richfield et al, Thy1-promoter, Rockenstein, 2002, Genomic construct (BACmid),

Symposium 15

M.F. Beal

P. Jenner, interpreting the results of the Adagio delayed start study: a mitochondrial mechanism of action for rasagiline, ADAGIO study, Mitochondrial changes key to pathology of PD, toxin induced cell death, familial PD, sporadic PD, Preventing mitochondrial abnormalities opens door to neuroprotective strategies, Rasagiline inhibtis apoptosis via mitochondrial related mechanism, prevent apoptosis by Cyt C reduction, in a dose dependent manner, modulationof prosurvival genes, Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

BJ Bacskai, In vivo imaging with multiphoton microscopy, Mouse Models of Abeta production, APPswe: PS1dE9, In vivo imaging of mouse brain, mice are anesthetized and prepared surgically for imaging., The mous is immobilized and placed on the stage of a multiphoton microscope, 3D imaging of the brain under the windows is performed, Individual neurons, neurites and psines can be imaged!, Potential model of neurodegeneration model outlined

SM Cardoso, Recent work by this author

Day 2

Symposium: management of neurogenic orthostatic hypotension in PD: scientific insights and therapeutic opportunities, Sponsored by Chelsea Therapeutics

P. Le Witt, Norepinephrine as a Neurotransmitter, Clinical implications of decreased brain norepinephrine, depression, cognitive impairment, etc, reference, Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode, Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease., Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

P. Low, Northera (Droxidopa): an orally available norepinephrine replacement therapy for the treatment of symptomatic neurogenic orthostatic hypotension, not marketed as a drug, investigational, under FDA review (disclaimer), Mechanism of action, Clinical trials, Japan, Eu, clinical trial, US, Clinical trial, Outcome scoring, orthostatic hypotension scale, Patient groups, Pure autonomic failure, Multiple System Atrophy, Parkinson's Disease, Chelsea therapeutics, Safety and efficacy

Symposium 24: Alpha Synuclein Biology

C. Ballard / Jones, Modified Alpha Synuclein in Dementia w Lewy bodies and Parkinson's Dementia, Post-translational modifications, Alter solubility, phosphorylation, ubiquitination, nitration etc., Truncated alpha synuclein, Genetics and synucleinopathy, Parkin, LRRK2, GBA, DJ-1, PINK1, PDD and DLB, Ubiquitin Proteasome System, Responsible for degradation and clearance of proteins, commonly implicated in neurodegenerative diseases, Alfa Synuclein detection, Annika Ohrfelt, DYRK1A gene, Phosphorylation of Alfa Synuclein, Tau Formation, Associated with Dementia

M.G. Schlossmacher, Sharing some unpublished data, His latest papers, α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study., Translational Research in Neurology and Neuroscience 2011: Movement Disorders, GBA-linked PD and Dementia with Lewy body cases are associated with alfa-synuclein-positive pathology, Does mutant GBA affect alfa-synuclein cells?, Cullen V, mol Brain 2009, Cullen, Kahn, Ann Neurol 2011, Question: Can the mutant GBA effect on alfa synuclein be reversed by pharmacological treatments of cells?, Rapamycin, GBA proteins promote a rise in exogenous andendogenous alfa syn concentrations in cellular and in vivo models, respectively., References, Farrer M, Nat Rev Gen 2006, Tomlinson JJ et al 2010, Aharon-Perets, NEJM 2004, Lewis A, Mol GEnet Metabol 2004, Eblan N, NEJM 2005, Sato C, Mov Disord 2005, Clark LN, Neurology 2007, Clark LN Arch. Neurol 2009, Neumann J et al Brain 2009, Sidransky E, NEJM 2009

P. Sardi, Association between gaucher disease and synucleinopathies, no notes made here

K. Vekrellis, Alfa-synuclein secretion is partially via exosomes, in lumen, in membrane, is secretion good or bad?, secreted alfa synuclein is toxic to recipient primary neurons, alfa synuclein may play a role in this!, We have not seen the alfa synuclein been internalised, how does toxic effect take place?, Increased calcium influx in neuronal cells recipient to secreted SNCA to plasma membrane, Determination of alfa synuclein concentration using a novel ultra-sensitive ELISA, 0.01 nanogram/ml sensitivity

T. Bartels, Alfa synuclein, folded, Natively unfolded monomer, oligomer, Natively folded helically, unfolded, pathway, in pathway, out of pathway, Peter Landsbury model: aggregation cascade leads to PD, Native PAGE of cell lysates, Blue native page, Clear Native Page, SDS PAGE of crosslinked cell lysates, SDS-PAGE Western blots of crosslinked cell lysates validate Native PAGE, STEM, Elektron Microscopy, Computer analysis, Sedimentation equilibrium AUC, Tetrameric alfasynuclein natively folded and does not undergo conformational change upon lipid interaction, Does native tetrameric Alfa Syn have increased functional capacity?, It binds lipids, Smith et al Biochemistry 2008, Surface Plasmon Resonance, Tetrameric alfa synuclein from cells ahs increased lipid binding capacity compared to unfolded monomer, Does folded alfa syn aggregate more than monomer, Yes, Alfa synuclein model same as this one, Proposed model of amyloidogenesis, Quintas A et al Biol. Chem. 1999, Pharmaceutical molecules, small molecules which stabilize Alfa Synuclein, PhD in biophysics

C. Kim, not reported

Innovative approaches and biomarkers in parkinson's Disease, Session sponsored by Orizon Genomics

K. Beyer

G. Linazasoro

T. Maes, Epigenetics and Parkinson's Disease, epigenetics important in learning and memory, epigenetics, young field, Epigenetics may play a role in sporadic PD, reduced methylation can occur, may lead to increased expression of Alfa synuclein, Changes in telomere length may play a role, Oryzon company, Reduction in Gene expression Park 5, UCHL1 reduced expression, DLB, AD, PD, Ubiquitin Carboxyterminal Hydrolase 1

Day 3

Day 4

Pre - Conference

Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets, under the auspices of MEMOSAD

#ADPD Tau, ABeta proteins and neurodegeneration (blog post)

Opening Ceremony

http://www.youtube.com/watch?v=Fp0nXEoZWDk&feature=channel_video_title

Author of notes

Paul de Roos

http://www.twitter.com/paulderoos

Live Conference updates

Conversation thread: #ADPD